AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24878085 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + metformin (850 mg three times a day)
Number of subjects: 93
Study 24878085 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 93
Study 24878085 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + metformin
Number of subjects: 93
Study 23869890 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body positive pressure (LBPP) at 20 mm Hg
Number of subjects: 1
Study 23869890 — intervention group
Group type: COMPARATOR
Intervention: Control (no LBPP)
Number of subjects: 1
Study 20848899 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) of Sanyinjiao (SP 6)
Number of subjects: 349
Study 20848899 — intervention group
Group type: COMPARATOR
Intervention: Sham‐EA
Number of subjects: 349
Study 20848899 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 349
Study 18047502 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA 100 U
Number of subjects: 59
Study 18047502 — intervention group
Group type: COMPARATOR
Intervention: DVPX 250 mg
Number of subjects: 59
Study 16815783 — intervention group
Group type: EXPERIMENTAL
Intervention: fat + caffeine trial
Number of subjects: 18
Study 12829154 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus amifostine (340 mg/m2 i.v., 15 min before RT)
Number of subjects: 205
Study 12829154 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 205
Study 12829154 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus amifostine
Number of subjects: 205
Study 10217382 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care interventions evaluated in the trials; specific interventions not detailed.
Number of subjects: 0
Study 10217382 — intervention group
Group type: COMPARATOR
Intervention: Not applicable; control group details not provided.
Number of subjects: 0
Study 7792744 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal exercise test
Number of subjects: 9
Study 7792744 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobic threshold exercise test
Number of subjects: 9
Study 7792744 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic threshold exercise test
Number of subjects: 9
Study 2143638 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 25 micrograms plus clonidine 1 microgram/kg
Number of subjects: 40
Study 2143638 — intervention group
Group type: COMPARATOR
Intervention: Epidural sufentanil 50 micrograms alone
Number of subjects: 40
Study 7438385 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.2 mg/kg over 1 minute
Number of subjects: 7
Study 7438385 — intervention group
Group type: COMPARATOR
Intervention: Volume‐matched saline (placebo)
Number of subjects: 7
Study 7438385 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 7
Study 30873906 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive web-based platform combining network meta-analysis findings with patient preferences
Number of subjects: 349
Study 30873906 — intervention group
Group type: COMPARATOR
Intervention: Series of bar charts (control)
Number of subjects: 349
Study 29891906 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural hirudin and subcutaneous LMWH-calcium (test group)
Number of subjects: 96
Study 29891906 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous LMWH-calcium (control group)
Number of subjects: 96
Study 27271683 — intervention group
Group type: EXPERIMENTAL
Intervention: Goals of care decision aid intervention (video decision aid and structured discussion); delivered ideally within 3 months after viewing.
Number of subjects: 151
Study 25473882 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1265744 (744) LA 800 mg IM followed by 3 monthly doses of 200 mg subcutaneously
Number of subjects: 47
Study 25473882 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1265744 (744) LA 800 mg IM followed by 3 monthly doses of 200 mg IM
Number of subjects: 47
Study 25473882 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1265744 (744) LA 800 mg IM followed by 3 monthly doses of 400 mg IM
Number of subjects: 47
Study 25473882 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1265744 (744) LA 800 mg IM followed by a second injection of 800 mg IM after 12 weeks
Number of subjects: 47
Study 25473882 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) LA 1200 mg IM at month 3 and 900 or 600 mg IM at month 4
Number of subjects: 47
Study 21904833 — intervention group
Group type: EXPERIMENTAL
Intervention: AFI (Autofluorescence Imaging)
Number of subjects: 94
Study 21904833 — intervention group
Group type: EXPERIMENTAL
Intervention: HRE (High Resolution Endoscopy)
Number of subjects: 94
Study 21904833 — intervention group
Group type: COMPARATOR
Intervention: AFI
Number of subjects: 94
Study 21904833 — intervention group
Group type: COMPARATOR
Intervention: HRE
Number of subjects: 94
Study 21904833 — intervention group
Group type: COMPARATOR
Intervention: AFI alone
Number of subjects: 94
Study 21904833 — intervention group
Group type: EXPERIMENTAL
Intervention: NBI (Narrow Band Imaging)
Number of subjects: 94
Study 21904833 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined AFI and NBI
Number of subjects: 94
Study 20724650 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck circumference measurement
Number of subjects: 3182
Study 20724650 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck circumference cutoff points
Number of subjects: 3182
Study 20724650 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis
Number of subjects: 3182
Study 18417444 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based dyspnea self-management program (eDSMP)
Number of subjects: 50
Study 18417444 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face dyspnea self-management program (fDSMP)
Number of subjects: 50
Study 18417444 — intervention group
Group type: EXPERIMENTAL
Intervention: Both programs (eDSMP and fDSMP)
Number of subjects: 50
Study 15838676 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal helmet CPAP
Number of subjects: 20
Study 15838676 — intervention group
Group type: COMPARATOR
Intervention: Nasal CPAP
Number of subjects: 20
Study 11842363 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.6% glucose drink
Number of subjects: 10
Study 11842363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10756890 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice about sodium restriction, weight reduction, physical exercise, relaxation, and a diet rich in fruits, vegetables, and low-fat dairy foods.
Number of subjects: 6
Study 10756890 — intervention group
Group type: EXPERIMENTAL
Intervention: Community studies with prevention interventions on entire populations.
Number of subjects: 6
Study 7709275 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 50
Study 7709275 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine
Number of subjects: 50
Study 2284386 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen challenge with ethinyl oestradiol
Number of subjects: 0
Study 2284386 — intervention group
Group type: COMPARATOR
Intervention: Patients with anorexia nervosa
Number of subjects: 0
Study 467112 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasotracheal suctioning
Number of subjects: 21
Study 6763435 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone, 10 mg thrice daily, continued until clinical remission, maximally 12 weeks.
Number of subjects: 23
Study 6763435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 30150128 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention by pharmacists
Number of subjects: 196
Study 30150128 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 196
Study 29436064 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of amitriptyline at bedtime for 2 months
Number of subjects: 220
Study 29436064 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 220
Study 27161894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (50,000 IU twice weekly)
Number of subjects: 38
Study 27161894 — intervention group
Group type: COMPARATOR
Intervention: Placebo (50 drops of a placebo solution twice weekly)
Number of subjects: 38
Study 25604219 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 108
Study 25604219 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 108
Study 22457014 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (400 μg)
Number of subjects: 12
Study 22457014 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium (80 μg)
Number of subjects: 12
Study 22457014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19814602 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity maintenance intervention
Number of subjects: 377
Study 17645712 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 29
Study 16042675 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg) and Itraconazole (100 mg, first dose 200 mg)
Number of subjects: 9
Study 16042675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 12353302 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg daily warfarin
Number of subjects: 98
Study 12353302 — intervention group
Group type: COMPARATOR
Intervention: Variable dose warfarin (PT 1.3‐1.5 times the normal PT)
Number of subjects: 98
Study 10419991 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal supplements containing iron + folate + zinc (15 mg zinc)
Number of subjects: 1295
Study 10419991 — intervention group
Group type: COMPARATOR
Intervention: Prenatal supplements containing iron + folate (without zinc)
Number of subjects: 1295
Study 10419991 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (zinc and no zinc)
Number of subjects: 1295
Study 7480534 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule associated with high frequency of reinforcement (greater monetary payoff)
Number of subjects: 12
Study 7480534 — intervention group
Group type: COMPARATOR
Intervention: Capsule associated with low frequency of reinforcement (lower monetary payoff)
Number of subjects: 12
Study 7480534 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administration results
Number of subjects: 12
Study 2124648 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperazine oestrone sulphate (PE1S, 2.5 mg/day)
Number of subjects: 8
Study 2124648 — intervention group
Group type: COMPARATOR
Intervention: Oestradiol valerate (E2V, 2.0 mg/day)
Number of subjects: 8
Study 2124648 — intervention group
Group type: EXPERIMENTAL
Intervention: PE1S in combination with levonorgestrel (LNG, 250 micrograms/day)
Number of subjects: 8
Study 2124648 — intervention group
Group type: COMPARATOR
Intervention: E2V
Number of subjects: 8
Study 6770707 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium cromoglycate (200 mg four times daily for 4 weeks)
Number of subjects: 15
Study 6770707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6770707 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium cromoglycate
Number of subjects: 15
Study 6770707 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither
Number of subjects: 15
Study 6770707 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician preference
Number of subjects: 15
Study 30039199 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg oral dose
Number of subjects: 33
Study 28616765 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 g kg‐1 RSM
Number of subjects: 125
Study 28616765 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 g kg‐1 RSM
Number of subjects: 125
Study 28616765 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 g kg‐1 RSM
Number of subjects: 125
Study 28616765 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 g kg‐1 RSM and 600 g kg‐1 RSM
Number of subjects: 125
Study 26222270 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment aiming at normoglycemia (n = 33)
Number of subjects: 69
Study 26222270 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control group, n = 36)
Number of subjects: 69
Study 23537332 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention (daily self-measurements of respiratory-rate, heart-rate, blood pressure, oxygen saturation, weight, body temperature, and health status questionnaire)
Number of subjects: 58
Study 23537332 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 58
Study 23537332 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention
Number of subjects: 58
Study 23537332 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 21414332 — intervention group
Group type: COMPARATOR
Intervention: High frequency rTMS of the right DLPFC
Number of subjects: 28
Study 18190554 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% w/w cetylpyridinium chloride (CPC) mouthwash (B)
Number of subjects: 32
Study 18190554 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% w/w CPC mouthwash (A)
Number of subjects: 32
Study 18190554 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash (C)
Number of subjects: 32
Study 16860830 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC alone (6 mg/kg)
Number of subjects: 47
Study 16860830 — intervention group
Group type: COMPARATOR
Intervention: DEC and albendazole (400 mg)
Number of subjects: 47
Study 16860830 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC alone (6 mg/kg) and DEC and albendazole (400 mg)
Number of subjects: 47
Study 12707148 — intervention group
Group type: EXPERIMENTAL
Intervention: Active warming of the upper abdomen with a carbon‐fiber warming blanket (42 degrees C)
Number of subjects: 60
Study 12707148 — intervention group
Group type: COMPARATOR
Intervention: No warming of the abdomen
Number of subjects: 60
Study 11279354 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal globus pallidus (GPi) stimulation
Number of subjects: 7
Study 9377176 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the tibial nerve during the last third of the first step stance phase with trains of five rectangular pulses, 1 ms in duration, at 20 Hz.
Number of subjects: 5
Study 9377176 — intervention group
Group type: COMPARATOR
Intervention: No electrical stimulation (control condition).
Number of subjects: 5
Study 8311536 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oestradiol-valerate
Number of subjects: 40
Study 8311536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3013044 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.005 mg/kg b.w.)
Number of subjects: 30
Study 3013044 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.01 mg/kg b.w.)
Number of subjects: 30
Study 3013044 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fentanyl and buprenorphine
Number of subjects: 30
Study 31707570 — intervention group
Group type: EXPERIMENTAL
Intervention: LSG with antrectomy (2 cm to pylorus)
Number of subjects: 127
Study 31707570 — intervention group
Group type: COMPARATOR
Intervention: LSG without antrectomy (6 cm to pylorus)
Number of subjects: 127
Study 31707570 — intervention group
Group type: COMPARATOR
Intervention: Comparison of group 1 (LSG with antrectomy) and group 2 (LSG without antrectomy)
Number of subjects: 127
Study 29912266 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly active asking
Number of subjects: 373
Study 29912266 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily self-report diary entries
Number of subjects: 373
Study 29912266 — intervention group
Group type: EXPERIMENTAL
Intervention: Call-in hotline
Number of subjects: 373
Study 29912266 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of active asking and diaries
Number of subjects: 373
Study 29912266 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of active asking and hotline
Number of subjects: 373
Study 29912266 — intervention group
Group type: EXPERIMENTAL
Intervention: Active asking vs diary entries
Number of subjects: 373
Study 29912266 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall rates
Number of subjects: 373
Study 28407657 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids and vitamin E co-supplementation (1,000 mg omega-3 from flaxseed oil containing 400 mg α-Linolenic acid plus 400 IU vitamin E)
Number of subjects: 68
Study 28407657 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids and vitamin E co-supplementation
Number of subjects: 68
Study 28407657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 25744115 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (2 mg)
Number of subjects: 258
Study 23748748 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (0.1-300 mg)
Number of subjects: 12
Study 19912513 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin K (1 mg) on the day before surgery (group K)
Number of subjects: 94
Study 19912513 — intervention group
Group type: COMPARATOR
Intervention: Heparin bridging after the last VKA dose on day -5 before surgery (group H)
Number of subjects: 94
Study 19080512 — intervention group
Group type: EXPERIMENTAL
Intervention: Labor analgesia with ropivacaine
Number of subjects: 124
Study 19080512 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pain relieving measure)
Number of subjects: 124
Study 16856145 — intervention group
Group type: COMPARATOR
Intervention: Rasagiline (1 mg/2 mg); n = 38
Number of subjects: 110
Study 16856145 — intervention group
Group type: COMPARATOR
Intervention: Rasagiline (0.5 mg/day); n = 22
Number of subjects: 110
Study 16856145 — intervention group
Group type: COMPARATOR
Intervention: Placebo; n = 21
Number of subjects: 110
Study 16856145 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline (1 mg/day); n = 12
Number of subjects: 110
Study 12496956 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 15
Study 12496956 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 15
Study 10906651 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed-dye laser (PDL) therapy (585 nm)
Number of subjects: 40
Study 10906651 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (liquid nitrogen cryotherapy or cantharidin)
Number of subjects: 40
Study 8854792 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperthermic pleural perfusion (CHPP) with 100 mg CDDP diluted in saline
Number of subjects: 9
Study 8854792 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperthermic pleural perfusion (CHPP) with 100 mg CDDP diluted in distilled water
Number of subjects: 9
Study 1471663 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (6 gm intravenous bolus)
Number of subjects: 22
Study 1471663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 6443596 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 micrograms/kg alfentanil
Number of subjects: 50
Study 6443596 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms/kg alfentanil
Number of subjects: 50
Study 6443596 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms/kg fentanyl
Number of subjects: 50
Study 6443596 — intervention group
Group type: COMPARATOR
Intervention: 1 ml/20 kg saline (Control)
Number of subjects: 50
Study 29732952 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep circumflex iliac artery flap
Number of subjects: 163
Study 29732952 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibular flap
Number of subjects: 163
Study 29732952 — intervention group
Group type: EXPERIMENTAL
Intervention: Scapular flap
Number of subjects: 163
Study 29732952 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac crest osseal flap
Number of subjects: 163
Study 30588947 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intrarectal lidocaine gel and periprostatic nerve block (cGPNB)
Number of subjects: 109
Study 30588947 — intervention group
Group type: COMPARATOR
Intervention: Caudal block (CB)
Number of subjects: 109
Study 27154849 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 17
Study 27154849 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 17
Study 25218139 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration (experimental group)
Number of subjects: 90
Study 25218139 — intervention group
Group type: COMPARATOR
Intervention: Control (no vibration)
Number of subjects: 90
Study 25218139 — intervention group
Group type: COMPARATOR
Intervention: Sham control (ultrasound vibration)
Number of subjects: 90
Study 21884013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 mg once daily for 24 weeks
Number of subjects: 224
Study 20580035 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/d) for 20 weeks
Number of subjects: 33
Study 20580035 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin/exercise (10 mg/d + exercise training 3d/wk from week 10 to week 20)
Number of subjects: 33
Study 20580035 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/d) and Rosuvastatin/exercise (10 mg/d + exercise training) combined
Number of subjects: 33
Study 20580035 — intervention group
Group type: COMPARATOR
Intervention: Control group (physically active hypercholesterolemic subjects)
Number of subjects: 33
Study 18007551 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500mg tid for 6 months
Number of subjects: 25
Study 18007551 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle interventions (disease controls)
Number of subjects: 25
Study 16121967 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan (0.2 mg/kg/hr)
Number of subjects: 34
Study 16121967 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan (0.4 mg/kg/hr for 12 hours followed by 0.2 mg/kg/hr)
Number of subjects: 34
Study 16121967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 16121967 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan
Number of subjects: 34
Study 11835038 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 14 days
Number of subjects: 833
Study 10999124 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (400 mg/day for six weeks) in Group I
Number of subjects: 34